Primary adverse events of Grade 3 and higher were elevation in lipase, alanine aminotransferase (AST), and alanine aspartate aminotransferase (ALT) levels, as well as thrombocytopenia and hypophosphatemia, thus necessitating a dosage reduction in 19 patients (73%). The gene discussed is GPT; the disease is Thrombocytopenia.